[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Terbutaline is combined with Antipyrine.]
[J01GA01, streptomycin, Terbutaline may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The serum concentration of Succinylcholine can be increased when it is combined with Terbutaline.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01CG01, sulbactam, Terbutaline may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Terbutaline.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Sulpiride.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Terbutaline is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Terbutaline is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Terbutaline.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Terbutaline may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Tetrabenazine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lurasidone.]
[A04AD10, dronabinol, The risk or severity of Tachycardia can be increased when Dronabinol is combined with Terbutaline.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Terbutaline.]
[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Terbutaline is combined with Theobromine.]
[R03DA04, theophylline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Theophylline.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05CA19, thiopental, The therapeutic efficacy of Thiopental can be decreased when used in combination with Terbutaline.]
[N05AB08, thioproperazine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Thiothixene.]
[G04BE06, moxisylyte, Terbutaline may increase the neuromuscular blocking activities of Moxisylyte.]
[V04CJ01, thyrotropin, The risk or severity of adverse effects can be increased when Terbutaline is combined with Thyrotropin.]
[V04CJ02, thyrotropin-releasing hormone, The risk or severity of adverse effects can be increased when Terbutaline is combined with Protirelin.]
[N05AL03, tiapride, Terbutaline may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[S01ED01, timolol, Timolol may decrease the bronchodilatory activities of Terbutaline.]
[P01AB02, tinidazole, Terbutaline may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Terbutaline may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[M02AX02, tolazoline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Tolazoline.]
[V04CA01, tolbutamide, Terbutaline may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Terbutaline.]
[N02AX02, tramadol, The therapeutic efficacy of Tramadol can be decreased when used in combination with Terbutaline.]
[N06AF04, tranylcypromine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Terbutaline.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Terbutaline.]
[S01BA05, triamcinolone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Terbutaline may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Terbutaline.]
[A16AX12, trientine, Terbutaline may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Trifluoperazine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Terbutaline.]
[D07AC02, fluclorolone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluclorolone.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Terbutaline.]
[R03BA07, mometasone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Terbutaline.]
[C02BA01, trimethaphan, Terbutaline may increase the neuromuscular blocking activities of Trimethaphan.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N06AA06, trimipramine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Terbutaline.]
[A03BB01, butylscopolamine, The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Terbutaline.]
[N06AX24, vilazodone, The risk or severity of hypertension can be increased when Terbutaline is combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, Terbutaline may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, Terbutaline may increase the neuromuscular blocking activities of Tubocurarine.]
[R03DX07, roflumilast, Terbutaline may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Terbutaline may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Vandetanib.]
[R02AA14, oxyquinoline, Terbutaline may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Rilpivirine.]
[S01AA28, vancomycin, Terbutaline may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ezogabine.]
[B01AF01, rivaroxaban, Terbutaline may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Indacaterol.]
[C08DA01, verapamil, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Verapamil.]
[N06AX09, viloxazine, Terbutaline may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[C04AX07, vincamine, Terbutaline may decrease the antihypertensive activities of Vincamine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AA03, warfarin, Terbutaline may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Terbutaline is combined with Xenon.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pipemidic acid.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Terbutaline.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[M05BA05, tiludronic acid, Terbutaline may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Terbutaline may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Crizotinib.]
[A02BC04, rabeprazole, Terbutaline may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terbutaline.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Terbutaline may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Terbutaline is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Terbutaline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Tolterodine.]
[J01DH04, doripenem, Terbutaline may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Atenolol.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Terbutaline.]
[M03AC04, atracurium, The therapeutic efficacy of Atracurium can be decreased when used in combination with Terbutaline.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Atropine is combined with Terbutaline.]
[M01CB03, auranofin, Terbutaline may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[H02AB11, prednylidene, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Prednylidene.]
[B03XA04, peginesatide, Terbutaline may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Terbutaline may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Terbutaline may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[A08AA11, lorcaserin, Terbutaline may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Terbutaline may increase the neuromuscular blocking activities of Mirabegron.]
[L02BB04, enzalutamide, Terbutaline may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Terbutaline is combined with Octopamine.]
[H02AA01, aldosterone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Aldosterone.]
[N05CA04, barbital, The therapeutic efficacy of Barbital can be decreased when used in combination with Terbutaline.]
[D02BA02, octinoxate, Terbutaline may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Terbutaline.]
[N04BD02, rasagiline, The risk or severity of hypertension can be increased when Terbutaline is combined with Rasagiline.]
[C08CA13, lercanidipine, Terbutaline may decrease the antihypertensive activities of Lercanidipine.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Zolmitriptan is combined with Terbutaline.]
[R06AC06, thonzylamine, The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Terbutaline.]
[G04BD10, darifenacin, The therapeutic efficacy of Darifenacin can be decreased when used in combination with Terbutaline.]
[V09IX04, fluorodeoxyglucose F18, Terbutaline may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Terbutaline is combined with Diethyl ether.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pasireotide.]
[V08CA11, gadofosveset, Terbutaline may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Terbutaline may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Bencyclane.]
[A10BH04, alogliptin, Terbutaline may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Terbutaline may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, Terbutaline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Terbutaline is combined with Benorilate.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Moxifloxacin.]
[H03AA04, tiratricol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Tiratricol.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Terbutaline.]
[L03AA12, ancestim, Terbutaline may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Celecoxib is combined with Terbutaline.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Terbutaline is combined with Naratriptan.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Terbutaline.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Terbutaline is combined with Benzydamine.]
[L01EE01, trametinib, Terbutaline may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[H05AA03, parathyroid hormone, The risk or severity of adverse effects can be increased when Terbutaline is combined with Parathyroid hormone.]
[V09AX05, florbetapir F-18, Terbutaline may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the tachycardic activities of Terbutaline.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Bepridil.]
[C02KX05, riociguat, Terbutaline may decrease the antihypertensive activities of Riociguat.]
[A10BJ03, lixisenatide, Terbutaline may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Terbutaline may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The risk or severity of hypertension can be increased when Terbutaline is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J05AP08, sofosbuvir, Terbutaline may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, The therapeutic efficacy of Terbutaline can be increased when used in combination with Droxidopa.]
[C07AB04, acebutolol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, Terbutaline may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Terbutaline may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Terbutaline may decrease the excretion rate of Formestane which could result in a higher serum level.]
[N07CA01, betahistine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Betahistine.]
[S03BA03, betamethasone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Betamethasone.]
[S01ED02, betaxolol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Betaxolol.]
[V03AB34, fomepizole, Terbutaline may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Terbutaline may decrease the antihypertensive activities of Bethanidine.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Terbutaline.]
[R03AC19, olodaterol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[D11AA01, glycopyrronium, The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Terbutaline.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05AA04, acepromazine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Acepromazine.]
[V04CX03, methacholine, Terbutaline may decrease effectiveness of Methacholine as a diagnostic agent.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Terbutaline.]
[S03AA06, gentamicin, Terbutaline may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AF03, edoxaban, Terbutaline may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Terbutaline.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[A03AA09, difemerine, The therapeutic efficacy of Difemerine can be decreased when used in combination with Terbutaline.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Terbutaline is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Terbutaline is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Terbutaline is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Terbutaline is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Terbutaline.]
[V03AB37, idarucizumab, Terbutaline may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Terbutaline.]
[L01XG03, ixazomib, Terbutaline may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Terbutaline may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Alfuzosin.]
[M04AB05, lesinurad, Terbutaline may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Terbutaline.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Terbutaline is combined with Alminoprofen.]
[N03AX23, brivaracetam, Terbutaline may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Terbutaline may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[A02AD05, aluminum magnesium silicate, Terbutaline may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Terbutaline.]
[N06AA19, amineptin, The risk or severity of hypertension can be increased when Amineptine is combined with Terbutaline.]
[C08CA01, amlodipine, Terbutaline may decrease the antihypertensive activities of Amlodipine.]
[C03CA02, bumetanide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Bumetanide.]
[N01BB01, bupivacaine, Terbutaline may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, Bupranolol may decrease the bronchodilatory activities of Terbutaline.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Buspirone is combined with Terbutaline.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Artemether.]
[M02AA03, clofezone, Terbutaline may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Terbutaline.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Terbutaline is combined with Balsalazide.]
[R03CC12, bambuterol, Terbutaline may increase the neuromuscular blocking activities of Bambuterol.]
[R03DA08, bamifylline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Bamifylline.]
[A06AH05, naldemedine, Terbutaline may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Terbutaline.]
[N06BC01, caffeine, The risk or severity of adverse effects can be increased when Terbutaline is combined with Caffeine.]
[C09AA07, benazepril, Terbutaline may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, Terbutaline may increase the neuromuscular blocking activities of Oxybuprocaine.]
[R05DB01, benzonatate, Terbutaline may increase the neuromuscular blocking activities of Benzonatate.]
[P01CA02, benznidazole, Terbutaline may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Linezolid is combined with Terbutaline.]
[J05AF06, abacavir, Terbutaline may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[H03BA03, benzylthiouracil, The risk or severity of adverse effects can be increased when Terbutaline is combined with Benzylthiouracil.]
[N07XX13, valbenazine, Terbutaline may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[H05AA04, abaloparatide, The risk or severity of adverse effects can be increased when Terbutaline is combined with Abaloparatide.]
[N04BD03, safinamide, The risk or severity of hypertension can be increased when Terbutaline is combined with Safinamide.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Bethanechol.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Delafloxacin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Terbutaline is combined with Acetylcholine.]
[L01BC06, capecitabine, Terbutaline may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Bitolterol.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C07AA17, bopindolol, Bopindolol may decrease the bronchodilatory activities of Terbutaline.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Terbutaline.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Budesonide.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Terbutaline is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Terbutaline is combined with Bumadizone.]
[N05CA03, butobarbital, The therapeutic efficacy of Butobarbital can be decreased when used in combination with Terbutaline.]
[N06AA15, butriptyline, The risk or severity of hypertension can be increased when Butriptyline is combined with Terbutaline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Acetyldigoxin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Acrivastine.]
[C09AA01, captopril, Terbutaline may decrease the antihypertensive activities of Captopril.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Carbamoylcholine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Macimorelin.]
[L02BB05, apalutamide, Terbutaline may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Terbutaline may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A03AA03, camylofine, The therapeutic efficacy of Camylofin can be decreased when used in combination with Terbutaline.]
[H03BB01, carbimazole, The risk or severity of adverse effects can be increased when Terbutaline is combined with Carbimazole.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Carbinoxamine.]
[C07AG02, carvedilol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of hypertension can be increased when Terbutaline is combined with Cannabidiol.]
[L04AA37, baricitinib, Terbutaline may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01GB14, plazomicin, Terbutaline may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Celiprolol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ivosidenib.]
[A16AX14, migalastat, Terbutaline may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Terbutaline may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Terbutaline.]
[N01BA04, chloroprocaine, Terbutaline may increase the neuromuscular blocking activities of Chloroprocaine.]
[D08AE05, chloroxylenol, Terbutaline may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Terbutaline.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Terbutaline is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Oxtriphylline.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Inotersen.]
[R03BB08, revefenacin, The therapeutic efficacy of Revefenacin can be decreased when used in combination with Terbutaline.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of adverse effects can be increased when Terbutaline is combined with Amifampridine.]
[A06AX05, prucalopride, Terbutaline may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cibenzoline.]
[C09AA08, cilazapril, Terbutaline may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Terbutaline is combined with Cinitapride.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Terbutaline.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Terbutaline is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Terbutaline.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[H02AB14, cloprednol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Cloprednol.]
[C09CA06, candesartan, Terbutaline may decrease the antihypertensive activities of Candesartan.]
[H02AB17, cortivazol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Cortivazol.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Entrectinib.]
[N07XX11, pitolisant, Terbutaline may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Terbutaline.]
[C03AA09, cyclothiazide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Terbutaline is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Terbutaline.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[H02AB13, deflazacort, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Deflazacort.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[M09AX08, golodirsen, Terbutaline may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Terbutaline.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Terbutaline may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Gatifloxacin.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Terbutaline is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Terbutaline is combined with Dutasteride.]
[R02AA03, dichlorobenzyl alcohol, Terbutaline may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Terbutaline may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Terbutaline.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Terbutaline.]
[C08CA16, clevidipine, Terbutaline may increase the neuromuscular blocking activities of Clevidipine.]
[C01BD07, dronedarone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Chlorcyclizine.]
[C02AA06, methoserpidine, Terbutaline may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Terbutaline.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Terbutaline is combined with Dopexamine.]
[D07XB03, fluprednidene, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluprednidene.]
[G04BD09, trospium, The therapeutic efficacy of Trospium can be decreased when used in combination with Terbutaline.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Terbutaline is combined with Droxicam.]
[V08CA05, mangafodipir, Terbutaline may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Terbutaline is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Terbutaline is combined with Dexketoprofen.]
[C08CA17, levamlodipine, Terbutaline may decrease the antihypertensive activities of Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fostemsavir.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Chloroquine.]
[C03AA04, chlorothiazide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Terbutaline is combined with Ethenzamide.]
[N02BA03, choline salicylate, Terbutaline may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Terbutaline.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Terbutaline is combined with Etofenamate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Terbutaline may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Terbutaline is combined with Naxitamab.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Terbutaline is combined with Fenbufen.]
[N06BA10, fenethylline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Fenethylline.]
[C01CA19, fenoldopam, Terbutaline may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Terbutaline is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Terbutaline is combined with Finasteride.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Flumequine.]
[R03BA03, flunisolide, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Flunisolide.]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluocinolone acetonide.]
[N02BG07, flupirtine, Terbutaline may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, Terbutaline may increase the sympathomimetic activities of Formoterol.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Terbutaline.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Terbutaline.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Terbutaline is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, Terbutaline may decrease the antihypertensive activities of Dasiglucagon.]
[G03GA06, follitropin beta, The risk or severity of adverse effects can be increased when Terbutaline is combined with Follitropin.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Terbutaline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Terbutaline is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Terbutaline may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Terbutaline may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Terbutaline may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Clemastine.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Terbutaline.]
[R03CC13, clenbuterol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Clenbuterol.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Terbutaline.]
[N01BB10, levobupivacaine, Terbutaline may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of hypertension can be increased when Clomipramine is combined with Terbutaline.]
[N03AE01, clonazepam, Terbutaline may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[S01EA04, clonidine, Terbutaline may decrease the antihypertensive activities of Clonidine.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Granisetron.]
[N05AH02, clozapine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Clozapine.]
[J01GB12, arbekacin, Terbutaline may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, Terbutaline may increase the neuromuscular blocking activities of Cocaine.]
[C02KB01, metyrosine, Terbutaline may decrease the antihypertensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Terbutaline is combined with Proquazone.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Terbutaline.]
[M04AC01, colchicine, Terbutaline may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Terbutaline.]
[A03BB06, homatropine methylbromide, The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Terbutaline.]
[J01XB01, colistin, Terbutaline may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Desflurane.]
[A04AA03, tropisetron, Terbutaline may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The risk or severity of hypertension can be increased when Terbutaline is combined with Ifenprodil.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Terbutaline is combined with Imidazole salicylate.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Terbutaline.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Telithromycin.]
[R03BA08, ciclesonide, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Terbutaline is combined with Indobufen.]
[R06AX27, desloratadine, The therapeutic efficacy of Desloratadine can be decreased when used in combination with Terbutaline.]
[J05AB14, valganciclovir, Terbutaline may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Terbutaline may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Terbutaline may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Terbutaline may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Terbutaline may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Terbutaline may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Terbutaline.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Terbutaline is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of hypertension can be increased when Terbutaline is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Terbutaline is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Itraconazole.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Emedastine.]
[N05BA10, ketazolam, Terbutaline may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Terbutaline is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Terbutaline.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Levocabastine.]
[S01BA03, cortisone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Cortisone.]
[N07BC04, lofexidine, Terbutaline may decrease the antihypertensive activities of Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Terbutaline is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Terbutaline is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C09AA03, lisinopril, Terbutaline may decrease the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, Terbutaline may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Terbutaline may decrease the antihypertensive activities of Manidipine.]
[A03AA04, mebeverine, The therapeutic efficacy of Mebeverine can be decreased when used in combination with Terbutaline.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Terbutaline is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may decrease the bronchodilatory activities of Terbutaline.]
[H02AB15, meprednisone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Adenosine.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Terbutaline.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Terbutaline is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cyclizine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Melperone.]
[C03AA07, cyclopenthiazide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N06AX07, minaprine, The risk or severity of hypertension can be increased when Minaprine is combined with Terbutaline.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Terbutaline.]
[N06AG02, moclobemide, The risk or severity of hypertension can be increased when Terbutaline is combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Terbutaline.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Terbutaline.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Terbutaline is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Terbutaline is combined with Morniflumate.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC05, moxonidine, Terbutaline may decrease the antihypertensive activities of Moxonidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Terbutaline.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Terbutaline is combined with Etoricoxib.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C02CC04, debrisoquin, Terbutaline may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of Tachycardia can be increased when Nabilone is combined with Terbutaline.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Terbutaline.]
[N07BB05, nalmefene, Terbutaline may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N06AX06, nefazodone, Nefazodone may increase the tachycardic activities of Terbutaline.]
[C01DX16, nicorandil, Terbutaline may decrease the antihypertensive activities of Nicorandil.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C01CA23, theodrenaline, The therapeutic efficacy of Terbutaline can be increased when used in combination with Theodrenaline.]
[M03AC11, cisatracurium, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Terbutaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Terbutaline is combined with Norfenefrine.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Terbutaline is combined with Olsalazine.]
[N06AA01, desipramine, The risk or severity of hypertension can be increased when Desipramine is combined with Terbutaline.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Terbutaline.]
[D07XC02, desoximetasone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Desoximetasone.]
[V04CH02, indigo carmine, Terbutaline may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Desoxycortone.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C09XA02, aliskiren, Terbutaline may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Terbutaline is combined with Oxaprozin.]
[S03BA01, dexamethasone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Dexamethasone.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Terbutaline.]
[G04BD04, oxybutynin, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Terbutaline.]
[A03AA01, oxyphencyclimine, The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Terbutaline.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Terbutaline.]
[R05DA09, dextromethorphan, The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Terbutaline.]
[H05AA02, teriparatide, The risk or severity of adverse effects can be increased when Terbutaline is combined with Teriparatide.]
[N06AB05, paroxetine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Terbutaline.]
[C01DA05, pentaerythritol tetranitrate, Terbutaline may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C04AD01, pentifylline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Pentifylline.]
[P03AC04, permethrin, Terbutaline may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[V03AH01, diazoxide, Terbutaline may decrease the antihypertensive activities of Diazoxide.]
[N06AA08, dibenzepin, The risk or severity of hypertension can be increased when Dibenzepin is combined with Terbutaline.]
[R05DA08, pholcodine, Terbutaline may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Terbutaline.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Terbutaline.]
[A03AA07, dicyclomine, The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Terbutaline.]
[J05AF02, didanosine, Terbutaline may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C02DG01, pinacidil, Terbutaline may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pinaverium.]
[A03AB14, pipenzolate, The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Terbutaline.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Erlotinib.]
[R03CC07, pirbuterol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Pirbuterol.]
[C03CA03, piretanide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Piretanide.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Terbutaline is combined with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Terbutaline.]
[D07XC04, diflucortolone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Difluocortolone.]
[A03AB11, poldine, The therapeutic efficacy of Poldine can be decreased when used in combination with Terbutaline.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Terbutaline.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Digitoxin.]
[C01AA05, digoxin, Terbutaline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Terbutaline may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Terbutaline.]
[H03BC01, potassium perchlorate, The risk or severity of adverse effects can be increased when Terbutaline is combined with Potassium perchlorate.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C08DB01, diltiazem, Terbutaline may decrease the antihypertensive activities of Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Terbutaline may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R06AB03, dimethindene, The therapeutic efficacy of Dimetindene can be decreased when used in combination with Terbutaline.]
[R03CC08, procaterol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, Terbutaline may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N06BC02, propentofylline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Propentofylline.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Terbutaline is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Terbutaline is combined with Proglumetacin.]
[R03DA03, proxyphylline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Proxyphylline.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Diphenhydramine.]
[C09AA06, quinapril, Terbutaline may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Terbutaline is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of hypertension can be increased when Quinupramine is combined with Terbutaline.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cisapride.]
[C09AA05, ramipril, Terbutaline may decrease the antihypertensive activities of Ramipril.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Terbutaline is combined with Reproterol.]
[S01AX06, resorcinol, Terbutaline may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Terbutaline.]
[N05AX08, risperidone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Levocetirizine.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Terbutaline.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Sunitinib.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Terbutaline.]
[G04BE08, tadalafil, Terbutaline may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Terbutaline.]
[C02KX02, ambrisentan, Terbutaline may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Terbutaline is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The risk or severity of adverse effects can be increased when Terbutaline is combined with Salmon calcitonin.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Dobutamine is combined with Terbutaline.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Terbutaline is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of hypertension can be increased when Dosulepin is combined with Terbutaline.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Terbutaline.]
[N06AA12, doxepin, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Doxepin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Terbutaline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Sevoflurane.]
[N05AD08, droperidol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Droperidol.]
[A08AA10, sibutramine, Sibutramine may increase the tachycardic activities of Terbutaline.]
[A12CA02, sodium sulfate, Terbutaline may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Terbutaline may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Dyphylline.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Sumatriptan is combined with Terbutaline.]
[V04CX07, edrophonium, Terbutaline may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Talinolol.]
[H01AA01, corticotropin, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Temafloxacin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Terbutaline.]
[G04CA03, terazosin, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Terazosin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Terodiline.]
[C07AA16, tertatolol, Tertatolol may decrease the bronchodilatory activities of Terbutaline.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Terbutaline is combined with Tetryzoline.]
[G04BD01, emepronium, The therapeutic efficacy of Emepronium can be decreased when used in combination with Terbutaline.]
[N06AX14, tianeptine, The risk or severity of hypertension can be increased when Tianeptine is combined with Terbutaline.]
[C09AA02, enalapril, Terbutaline may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Terbutaline is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of hypertension can be increased when Terbutaline is combined with Toloxatone.]
[N06BA09, atomoxetine, Atomoxetine may increase the tachycardic activities of Terbutaline.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Terbutaline is combined with Tramazoline.]
[C09AA10, trandolapril, Terbutaline may decrease the antihypertensive activities of Trandolapril.]
[N05CC01, chloral hydrate, Terbutaline may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[A03AB08, tridihexethyl, The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Terbutaline.]
[H02CA01, trilostane, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Trilostane.]
[G03GA05, follitropin alfa, The risk or severity of adverse effects can be increased when Terbutaline is combined with Follitropin.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Triptorelin.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Terbutaline.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Terbutaline is combined with Tulobuterol.]
[C02CA06, urapidil, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Terbutaline.]
[S01FB02, ephedrine, The therapeutic efficacy of Terbutaline can be increased when used in combination with Ephedrine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Terbutaline.]
[N06AX16, venlafaxine, Venlafaxine may increase the tachycardic activities of Terbutaline.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Terbutaline is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Terbutaline is combined with Xylometazoline.]
[S01EA01, epinephrine, The therapeutic efficacy of Terbutaline can be increased when used in combination with Epinephrine.]
[C09AA15, zofenopril, Terbutaline may decrease the antihypertensive activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Terbutaline is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Terbutaline.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C02AC02, guanfacine, Terbutaline may decrease the antihypertensive activities of Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Terbutaline.]
[G02AB03, ergonovine, Ergometrine may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[N02CA02, ergotamine, Ergotamine may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Valproic acid.]
[L03AX05, pidotimod, Terbutaline may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Erythromycin.]
[N05CD04, estazolam, Terbutaline may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluticasone furoate.]
[R03BA05, fluticasone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluticasone.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Terbutaline is combined with Gepefrine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ibutilide.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Terbutaline.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Terbutaline.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Terbutaline.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Terbutaline is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Etomidate is combined with Terbutaline.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Terbutaline.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fleroxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Terfenadine.]
[P01AX07, trimetrexate, Terbutaline may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Terbutaline may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Leuprolide.]
[M01CB01, gold sodium thiomalate, Terbutaline may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Terbutaline may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Terbutaline.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Fentanyl is combined with Terbutaline.]
[R03CC02, albuterol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Salbutamol.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N07AX03, cevimeline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Cevimeline.]
[G04BD02, flavoxate, The therapeutic efficacy of Flavoxate can be decreased when used in combination with Terbutaline.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Terbutaline is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Terbutaline.]
[J02AX01, flucytosine, Terbutaline may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[H02AA02, fludrocortisone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fludrocortisone.]
[V03AB25, flumazenil, Terbutaline may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Flumethasone.]
[D07AC08, fluocinonide, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of hypertension can be increased when Melitracen is combined with Terbutaline.]
[H02AB03, fluocortolone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluocortolone.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[S01CB05, fluorometholone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluorometholone.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Terbutaline.]
[N05AF01, flupenthixol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Flupentixol.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Terbutaline.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L01BC03, tegafur, Terbutaline may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Terbutaline is combined with Adrafinil.]
[M03AA01, alcuronium, The therapeutic efficacy of Alcuronium can be decreased when used in combination with Terbutaline.]
[G01AX06, furazolidone, The risk or severity of hypertension can be increased when Furazolidone is combined with Terbutaline.]
[C03CA01, furosemide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Furosemide.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Terbutaline.]
[M03AC02, gallamine, The therapeutic efficacy of Gallamine can be decreased when used in combination with Terbutaline.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Gallopamil.]
[S01AD09, ganciclovir, Terbutaline may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[C10AB04, gemfibrozil, Terbutaline may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dasatinib.]
[N04BC06, cabergoline, Cabergoline may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[C01CA21, cafedrine, The risk or severity of adverse effects can be increased when Terbutaline is combined with Cafedrine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Alfentanil is combined with Terbutaline.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lapatinib.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Terbutaline.]
[A10BB07, glipizide, Terbutaline may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Terbutaline.]
[C05AE01, nitroglycerin, Terbutaline may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dofetilide.]
[C02CA04, doxazosin, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Doxazosin.]
[H01AB01, thyrotropin alfa, The risk or severity of adverse effects can be increased when Terbutaline is combined with Thyrotropin alfa.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Terbutaline.]
[C07AB09, esmolol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Esmolol.]
[M01CB04, aurothioglucose, Terbutaline may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Terbutaline may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Terbutaline may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Terbutaline may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Terbutaline is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Quetiapine.]
[N06BX13, idebenone, Terbutaline may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Terbutaline.]
[L01CE02, irinotecan, Terbutaline may increase the neuromuscular blocking activities of Irinotecan.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Terbutaline.]
[G03DC01, allylestrenol, Terbutaline may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Terbutaline.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05CA16, hexobarbital, The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Terbutaline.]
[R03CC05, hexoprenaline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Hexoprenaline.]
[C08CA10, nilvadipine, Terbutaline may decrease the antihypertensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Terbutaline is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Oxatomide.]
[C09AA04, perindopril, Terbutaline may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Terbutaline may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Hydroflumethiazide.]
[B05XA17, potassium acetate, Terbutaline may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[G04BD06, propiverine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Terbutaline may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Hydroxyzine.]
[C02AC06, rilmenidine, Terbutaline may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Terbutaline is combined with Ibuprofen.]
[B05XA08, sodium acetate, Terbutaline may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Terbutaline may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Sufentanil is combined with Terbutaline.]
[N06AA02, imipramine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Imipramine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Terlipressin.]
[R01AD07, tixocortol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Terbutaline.]
[L01CE01, topotecan, Terbutaline may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Terbutaline.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Terbutaline.]
[C02CA02, indoramin, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Indoramin.]
[A11HA07, inositol, Terbutaline may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Milnacipran may increase the tachycardic activities of Terbutaline.]
[A03AA30, piperidolate, The therapeutic efficacy of Piperidolate can be decreased when used in combination with Terbutaline.]
[S01XA28, varenicline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Varenicline.]
[A10BH01, sitagliptin, Terbutaline may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05CH02, ramelteon, Terbutaline may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Terbutaline.]
[G02CX01, atosiban, The risk or severity of adverse effects can be increased when Terbutaline is combined with Atosiban.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Anagrelide.]
[C07AA01, alprenolol, Alprenolol may decrease the bronchodilatory activities of Terbutaline.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Terbutaline may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of hypertension can be increased when Iprindole is combined with Terbutaline.]
[N06AF05, iproniazid, The risk or severity of hypertension can be increased when Terbutaline is combined with Iproniazid.]
[N06AF01, isocarboxazid, The risk or severity of hypertension can be increased when Terbutaline is combined with Isocarboxazid.]
[R03CC06, isoetharine, The risk or severity of adverse effects can be increased when Isoetharine is combined with Terbutaline.]
[C09AA16, imidapril, Terbutaline may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Terbutaline.]
[J04AC01, isoniazid, Terbutaline may decrease the excretion rate of Isoniazid which could result in a higher serum level.]
[J05AX05, inosine pranobex, Terbutaline may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The risk or severity of adverse effects can be increased when Terbutaline is combined with Isoprenaline.]
[C01DA14, isosorbide mononitrate, Terbutaline may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, Terbutaline may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Terbutaline is combined with Isoxsuprine.]
[S01AA24, kanamycin, Terbutaline may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, Terbutaline may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, Terbutaline may decrease the antihypertensive activities of Ketanserin.]
[B01AC22, prasugrel, Terbutaline may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Terbutaline is combined with Ketoprofen.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Mizolastine.]
[C01CA22, arbutamine, The risk or severity of adverse effects can be increased when Terbutaline is combined with Arbutamine.]
[N04BC09, rotigotine, The risk or severity of hypertension can be increased when Terbutaline is combined with Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Terbutaline is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Amantadine.]
[C02AA05, deserpidine, Terbutaline may decrease the antihypertensive activities of Deserpidine.]
[A06AX03, lubiprostone, Terbutaline may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[C03CC01, ethacrynic acid, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Etacrynic acid.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lidoflazine.]
[S01AA21, amikacin, Terbutaline may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, Lisuride may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[N06AA07, lofepramine, The risk or severity of hypertension can be increased when Lofepramine is combined with Terbutaline.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Loperamide.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05AH01, loxapine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Loxapine.]
[B05XA11, magnesium chloride, Terbutaline may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Terbutaline may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[L01BA05, pralatrexate, Terbutaline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Maprotiline.]
[C02BB01, mecamylamine, Terbutaline may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The therapeutic efficacy of Meclizine can be decreased when used in combination with Terbutaline.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Terbutaline is combined with Meclofenamic acid.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Terbutaline.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, Terbutaline may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Terbutaline is combined with Mephentermine.]
[N03AA01, mephobarbital, The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Terbutaline.]
[N01BB03, mepivacaine, Terbutaline may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Terbutaline may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Mesoridazine.]
[N05AX13, paliperidone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Terbutaline.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dolasetron.]
[N07BC02, methadone, The therapeutic efficacy of Methadone can be decreased when used in combination with Terbutaline.]
[N06BA03, methamphetamine, The risk or severity of hypertension can be increased when Terbutaline is combined with Metamfetamine.]
[A03AB07, methantheline, The therapeutic efficacy of Methantheline can be decreased when used in combination with Terbutaline.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Terbutaline.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, Metergoline may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Terbutaline is combined with Methimazole.]
[L01BA04, pemetrexed, Terbutaline may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Terbutaline.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of hypertension can be increased when Terbutaline is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Methyclothiazide.]
[C02AB01, methyldopa, Terbutaline may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, The risk or severity of hypertension can be increased when Terbutaline is combined with Methylene blue.]
[G02AB01, methylergonovine, Methylergometrine may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[R03DA05, aminophylline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Aminophylline.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Terbutaline.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Methylprednisolone.]
[D07AC14, methylprednisolone aceponate, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Methylprednisolone aceponate.]
[G03EK01, methyltestosterone, Terbutaline may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, Methysergide may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Metoclopramide.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Metronidazole.]
[V04CD01, metyrapone, Terbutaline may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Terbutaline is combined with Mianserin.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Terbutaline is combined with Aminophenazone.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Terbutaline.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Mifepristone.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C09CA03, valsartan, Terbutaline may decrease the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Terbutaline may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Terbutaline is combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Amiodarone.]
[N06AA09, amitriptyline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Amitriptyline.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Terbutaline may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Terbutaline may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pazopanib.]
[L04AA06, mycophenolic acid, Terbutaline may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The therapeutic efficacy of Vecuronium can be decreased when used in combination with Terbutaline.]
[N05CA02, amobarbital, The therapeutic efficacy of Amobarbital can be decreased when used in combination with Terbutaline.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Terbutaline.]
[G04CA04, silodosin, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Silodosin.]
[R03BB01, ipratropium bromide, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Terbutaline.]
[N06AA17, amoxapine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Amoxapine.]
[C07AA12, nadolol, Nadolol may decrease the bronchodilatory activities of Terbutaline.]
[J01CA04, amoxicillin, Terbutaline may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Terbutaline may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Terbutaline is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Terbutaline.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Terbutaline.]
[N06AX21, duloxetine, Duloxetine may increase the tachycardic activities of Terbutaline.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[S03AA01, neomycin, Terbutaline may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Terbutaline is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Levosimendan.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05AX14, iloperidone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[L03AX16, plerixafor, Terbutaline may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Terbutaline may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the tachycardic activities of Terbutaline.]
[C09CA07, telmisartan, Terbutaline may decrease the antihypertensive activities of Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C01CE01, inamrinone, Terbutaline may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Terbutaline is combined with Nialamide.]
[C08CA04, nicardipine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Terbutaline is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Terbutaline is combined with Niflumic acid.]
[C08CA06, nimodipine, Terbutaline may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Terbutaline may decrease the antihypertensive activities of Nisoldipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Nitrendipine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05CF03, zaleplon, Terbutaline may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C02DD01, nitroprusside, Terbutaline may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Terbutaline is combined with Nitrous oxide.]
[C01CA03, norepinephrine, The therapeutic efficacy of Terbutaline can be increased when used in combination with Norepinephrine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Norfloxacin.]
[C02KX01, bosentan, Terbutaline may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Terbutaline is combined with Nylidrin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terbutaline.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ofloxacin.]
[N06AA05, opipramol, The risk or severity of hypertension can be increased when Opipramol is combined with Terbutaline.]
[N02AA02, opium, Terbutaline may decrease the excretion rate of Opium which could result in a higher serum level.]
[R03CB03, metaproterenol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Terbutaline.]
[G04CA02, tamsulosin, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Tamsulosin.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Oxprenolol may decrease the bronchodilatory activities of Terbutaline.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Terbutaline is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Terbutaline is combined with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Terbutaline is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Terbutaline.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terbutaline.]
[N05AH05, asenapine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Asenapine.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be decreased when used in combination with Terbutaline.]
[J04AB30, capreomycin, Terbutaline may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Papaverine.]
[H02AB05, paramethasone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Paramethasone.]
[C02KC01, pargyline, Terbutaline may decrease the antihypertensive activities of Pargyline.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Terbutaline.]
[G04BD11, fesoterodine, The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Terbutaline.]
[C07AA23, penbutolol, Penbutolol may decrease the bronchodilatory activities of Terbutaline.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Terbutaline may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Terbutaline.]
[L01XX08, pentostatin, Terbutaline may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Pentoxifylline.]
[N04BC02, pergolide, Pergolide may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Perhexiline.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Phenelzine is combined with Terbutaline.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pheniramine.]
[N03AA02, phenobarbital, The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Terbutaline.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Phenoxybenzamine.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Terbutaline.]
[V03AB36, phentolamine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Terbutaline.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Terbutaline.]
[R01BA01, phenylpropanolamine, The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Terbutaline.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Levofloxacin.]
[B02BA01, vitamin K1, Terbutaline may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C08CX01, mibefradil, Terbutaline may decrease the antihypertensive activities of Mibefradil.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Terbutaline is combined with Pilocarpine.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pimozide.]
[C07AA03, pindolol, Pindolol may decrease the bronchodilatory activities of Terbutaline.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Saquinavir.]
[N06BX03, piracetam, Terbutaline may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Terbutaline may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Terbutaline.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Terbutaline.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Grepafloxacin.]
[N02CX01, pizotyline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Pizotifen.]
[C09CA04, irbesartan, Terbutaline may decrease the antihypertensive activities of Irbesartan.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C03AA05, polythiazide, The risk or severity of hypokalemia can be increased when Terbutaline is combined with Polythiazide.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Terbutaline.]
[A10BH03, saxagliptin, Terbutaline may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[V03AB21, potassium iodide, The risk or severity of adverse effects can be increased when Terbutaline is combined with Potassium Iodide.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Terbutaline.]
[C07AB01, practolol, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Prajmaline.]
[C02CA01, prazosin, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Prazosin.]
[S03BA02, prednisolone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Prednisolone.]
[H02AB07, prednisone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Prenylamine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Primaquine.]
[N03AA03, primidone, The therapeutic efficacy of Primidone can be decreased when used in combination with Terbutaline.]
[M04AB01, probenecid, Terbutaline may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Probucol.]
[C01BA02, procainamide, Terbutaline may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Terbutaline may increase the neuromuscular blocking activities of Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Terbutaline.]
[C10AB05, fenofibrate, Terbutaline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Prochlorperazine.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Terbutaline.]
[N05AA03, promazine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Promethazine.]
[C01BC03, propafenone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Propafenone.]
[A03AB05, propantheline, The therapeutic efficacy of Propantheline can be decreased when used in combination with Terbutaline.]
[N05AC01, periciazine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Terbutaline.]
[C07AA05, propranolol, Propranolol may decrease the bronchodilatory activities of Terbutaline.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Terbutaline is combined with Propylthiouracil.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Terbutaline is combined with Rizatriptan.]
[B01AC09, epoprostenol, Terbutaline may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of hypertension can be increased when Protriptyline is combined with Terbutaline.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Terbutaline.]
[N05AX12, aripiprazole, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Aripiprazole.]
[N07XX07, dalfampridine, Terbutaline may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, The therapeutic efficacy of Diphemanil can be decreased when used in combination with Terbutaline.]
[A03AB09, isopropamide, The therapeutic efficacy of Isopropamide can be decreased when used in combination with Terbutaline.]
[S01FA03, methscopolamine, The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Terbutaline.]
[N05CA07, talbutal, The therapeutic efficacy of Talbutal can be decreased when used in combination with Terbutaline.]
[P02CC01, pyrantel, Terbutaline may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Mepyramine.]
[C01BA01, quinidine, Terbutaline may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Quinine.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[C02AA01, rescinnamine, Terbutaline may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Terbutaline may decrease the antihypertensive activities of Reserpine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Terbutaline is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of adverse effects can be increased when Ritodrine is combined with Terbutaline.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Terbutaline is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Terbutaline.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Terbutaline is combined with Salicylic acid.]
[S01FA02, scopolamine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Terbutaline.]
[N05CA06, secobarbital, The therapeutic efficacy of Secobarbital can be decreased when used in combination with Terbutaline.]
[N04BD01, selegiline, The risk or severity of hypertension can be increased when Terbutaline is combined with Selegiline.]
[J01GB08, sisomicin, Terbutaline may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Terbutaline may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Terbutaline may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, Sotalol may decrease the bronchodilatory activities of Terbutaline.]
[C03DA01, spironolactone, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Spironolactone.]
[D07AB02, hydrocortisone butyrate, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Hydrocortisone butyrate.]
